Suppliers / Keshava Organics

Keshava Organics

India 21 employees Updated 9 July 2026

Keshava Organics is an API manufacturer based in India. It holds 5 active US drug master files across a filed portfolio of 5 molecules. Its most recent recorded inspection, by US FDA, closed on 13 January 2023 as VAI. Customs aggregates show $7.6M of exports covering 149 molecules to 26 destinations in 2025.

5
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 13 January 2023 VAI US FDA
  • 31 May 2017 OAI US FDA
  • 18 April 2014 OAI US FDA
  • 17 May 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Palghar, India 3003677831

What they file, and where

Molecule Regulators Docs
Chlorpheniramine SFDA (Saudi Arabia), US FDA 2
Brompheniramine US FDA 1
Dexchlorpheniramine US FDA 1
Mepyramine US FDA 1
Pheniramine US FDA 1

Also appears on these molecule pages

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $1.1M 18
2025 Not reported $7.6M 26
2024 Not reported $6.7M 25
2023 Not reported $5.5M 25

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Keshava Organics comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 13 January 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts